Pharma Spectrum Essay

16912 Words68 Pages
Pharma Spectrum Organisation of Pharmaceutical Producers of India Volume 5 Issue 7 July 2012 INDEX INTERNATIONAL 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. IPR Regulatory New Products R&D / Clinical Trials Mergers & Acquisitions / Collaborations Pricing Trade & Others Biotechnology Medical Diagnostics / Devices New Appointments 1 2 3 4 5 6 7 10 10 10 DOMESTIC 1. 2. 3. 4. 5. 6. 7. 8. 9 10. 11. IPR Regulatory New Products R&D / Clinical Trials Mergers & Acquisitions / Collaborations Pricing Trade & Others Biotechnology Medical Diagnostics / Devices New Appointments OPPI Related News 10 11 14 14 16 18 19 22 23 24 24 Organisation of Pharmaceutical Producers of India 0 Pharma Spectrum International IPR As Compulsory Licensing Drugmakers Adapt June 22, 2012, Fierce Pharma There is the concept associated with evolution that you must adapt or die. Now some experts are suggesting the same thing for drugmakers when it comes to the growing threat of compulsory licensing. Now that China is following India into this realm, which allows countries to essentially strip companies of patents if they deem it in the public interest, the tension among big drug developers is rising. LiveMint quotes a research company in the U.K. saying the research-oriented companies "will have to restructure their business plans in emerging markets," to compete. Strategies will include making their drugs cheaper themselves in the countries where the threat of compulsory licensing exists and making sure they are available to more poor patients to cut off the incentive to invoke the maneuver. But as EvaluatePharma reminds us in its latest World Preview report, released at this week's BIO conference, 2012 is far from the end of pharma's patent woes. Next year provides something of a respite, with only $29 billion's worth of drugs losing exclusivity. Spreads, Merck Loses A Patent Blockbuster Nasonex June

More about Pharma Spectrum Essay

Open Document